http://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

Federal Budget 2019 - Comment & Analysis

Dr Boreham's Crucible: Osprey Medical

2018 - The Year In Review

Bionomics Falls 69% As BNC210 Fails PTSD Primaary Endpoints

Neuren, Acadia $630m North America Trofinetide Licence

Benitec Up 124% On Up-To $892m Axovant Gene Therapy Deal

Prana Back In The Clinic With PBT434 For Parkinson's Disease

  


 

March BDI-40 Up 6%, ASX200 Up 0.2%
Big Caps Flat, NBI Down 0.1%

 Avita Up 107%, Paradigm 66%, Uscom 47%; Oncosil Down 78%, Cynata 22%

April 1, 2019


 
For the year to March 31, 2019, the BDI-40 was up 1.0 percent, the ASX200 rose 7.3 percent, the Big Caps improved 20.05 percent and the NBI was up 4.7 percent.
 
In March, 19 of the Biotech Daily Top 40 Index (BDI-40) stocks were up, 13 by more than 10 percent, 16 fell, with seven losing more than 10 percent, and five were unchanged.
 
Avita was the best, up 107.1 percent for the month and 784.7 percent for the year to $522 million, followed by Paradigm up 65.8 percent for the month and 662.9 percent for the year to $267 million. Uscom was up 47.1 percent in March, followed by Compumedics (37.9%), Osprey (30.2%), Genetic Signatures (23.2%), Medical Developments (18.3%), Telix (17.3%), Volpara (16.1%), Antisense (14.3%), LBT (14.3%), Prana (13.6%) and Mesoblast (12.2%).
 
Oncosil led the falls on bad CE mark news, down $89 million or 78.1 percent to $25 million, followed by Cynata (22.4%), Prescient (14.3%), Impedimed (13.7%), Optiscan (13.6%), Universal Biosensors (12.5%) and Kazia (12.1%).
 
In March, Cochlear improved 1.2 percent to $9,959 million, CSL slipped 0.06 percent to $87,719 million and Resmed shed 0.4 percent to $20,704 million.
 
Outside the Top 40, Resonance continued its record run, up 19.4 percent for the month and 362.5 percent for the year to $37 million, Alcidion was up 71.9 percent for the month and 129.2 percent for the year to $55 million, Bluechiip was up 95.8 percent for the year to $47 million, with Elixinol Global up 222.9 percent for the year to $565 million and it hasn’t really become a medical marijuana company, yet. Medadvisor and Recce were also up.
 
Nine of the 16 stocks in Cannabis Corner fell, four were up and three were unchanged, with Cann Group up 31.6 percent and Elixinol up 32.0 percent.
 
On the Nasdaq, Queensland’s Protagonist was up 45.3 percent to $414 million; from a low base, Vaxart (Biota) was up 35.2 percent to $23 million; Israel’s Redhill (with Australian assets) was up 8.5 percent to $332 million; and Eyepoint (Psivida) fell 30.5 percent to $241 million.
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Mar 31, 2019 
 
Big Caps (Cochlear, CSL, Resmed) Mar 31, 2016 To Mar 31, 2019


 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At Mar 31, 2019

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Amplia, Benitec, Cynata, Mesoblast, Nanosonics, Neuren,
   Patrys, Polynovo, Prana, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in